APA Citatie

Ko, B., & Halmos, B. (2018). Capmatinib and gefitinib combination therapy: Will EGFR-mutated MET-dysregulated NSCLC “capitulate”? Transl Lung Cancer Res.

Chicago Style citaat

Ko, Brian, en Balazs Halmos. "Capmatinib and Gefitinib Combination Therapy: Will EGFR-mutated MET-dysregulated NSCLC “capitulate”?" Transl Lung Cancer Res 2018.

MLA citatie

Ko, Brian, en Balazs Halmos. "Capmatinib and Gefitinib Combination Therapy: Will EGFR-mutated MET-dysregulated NSCLC “capitulate”?" Transl Lung Cancer Res 2018.

Let op: Deze citaties zijn niet altijd 100% accuraat.